Medical management of glaucoma

New England Journal of Medicine

Volumn 339, Issue 18, 1998, Pages 1298-1307

  Alward, Wallace L M ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ADRENALIN; ADRENALIN BORATE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; APRACLONIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BETOPTIC S; BRIMONIDINE; BRINZOLAMIDE; CANNABINOID; CANNABIS; CARBACHOL; CARBONATE DEHYDRATASE INHIBITOR; CARBOPTIC; CARTEOLOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; DEMECARIUM; DICLOFENAMIDE; DIPIVEFRINE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; E PILO; ECOTHIOPATE; ECOTHIOPATE IODIDE; ESCRINE; GLAUCTABS; LATANOPROST; LEVOBUNOLOL; METHAZOLAMIDE; METIPRANOLOL; MZM; NEW DRUG; PHYSOSTIGMINE; PILOCARPINE; PILOSTAT; PROSTAGLANDIN DERIVATIVE; TETRAHYDROCANNABINOL; TIMOLOL; TIMOLOL MALEATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANOREXIA; AQUEOUS HUMOR FLOW; BLOOD TOXICITY; BRONCHOSPASM; CLOSED ANGLE GLAUCOMA; DROWSINESS; DRUG MECHANISM; GLAUCOMA; HEADACHE; HUMAN; HYPOTENSION; INTRAOCULAR PRESSURE; MENTAL DISEASE; MYALGIA; MYOPIA; OPEN ANGLE GLAUCOMA; ORAL DRUG ADMINISTRATION; PERIMETRY; PRIORITY JOURNAL; REVIEW; TONOMETRY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADRENERGIC AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANTERIOR EYE SEGMENT; CARBONIC ANHYDRASE INHIBITORS; CHOLINERGIC AGONISTS; GLAUCOMA; HUMANS; PROSTAGLANDINS, SYNTHETIC; TETRAHYDROCANNABINOL;

EID: 0032578846     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199810293391808     Document Type: Review

References (118)

1. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996;80:389-93.
2. Leske MC. The epidemiology of open-angle glaucoma: a review. Am J Epidemiol 1983;118:166-91.
3. Armaly MF. On the distribution of applanation pressure: I. Statistical features and the effect of age, sex, and family history of glaucoma. Arch Ophthalmol 1965;73:11-8.
4. Klein BE, Klein R, Linton KL. Intraocular pressure in an American community: the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci 1992; 33:2224-8.
5. Epstein DL, Krug JH Jr, Hertzmark E, Remis LL, Edelstein DJ. A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects. Ophthalmology 1989;96:1460-7.
6. Kass MA, Gordon MO, Hoff MR, et al. Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals: a randomized, double-masked, long-term clinical trial. Arch Ophthalmol 1989;107:1590-8.
7. Schulzer M, Drance SM, Douglas GR. A comparison of treated and untreated glaucoma suspects. Ophthalmology 1991;98:301-7.
8. Jocson VL, Sears ML. Experimental aqueous perfusion in enucleated human eyes: results after obstruction of Schlemm's canal. Arch Ophthalmol 1971;86:65-71.
9. Bill A, Phillips CI. Uveoscleral drainage of aqueous humour in human eyes. Exp Eye Res 1971;12:275-81.
10. Zimmerman TJ, Kaufman HE. Timolol: a beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol 1977;95:601-4.
11. Shin DH. Bilateral effects of monocular timolol treatment. Am J Ophthalmol 1986;102:275-6.
12. Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthalmol 1984;102:551-3.
13. Villumsen J, Alm A. The effect of adding prostagfandin F2 alphaisopropylester to timolol in patients with open angle glaucoma. Arch Ophthalmol 1990;108:1102-5.
14. Kronfeld PC. The efficacy of combinations of ocular hypotcnsive drugs: a tonographic approach. Arch Ophthalmol 1967;78:140-6.
15. Keates EU. Evaluation of timolol maleate combination therapy in chronic open-angle glaucoma. Am J Ophthalmol 1979;88:565-71.
16. Kass MA. Efficacy of combining timolol with other antiglaucoma medications. Surv Ophthalmol 1983;28:Suppl:274-9.
17. Knupp JA, Shields MB, Mandell AI, Hurvitz L, Spaeth GL. Combined timolol and epinephrine therapy for open angle glaucoma. Surv Ophthalmol 1983;28:Suppl:280-5.
18. Crawford K, Kaufman PL. Pilocarpine antagonizes prostaglandin F2 α-induced ocular hypotension in monkeys: evidence for enhancement of uveoscleral outflow by prostaglandin F2 α. Arch Ophthalmol 1987;105: 1112-6.
19. Friström B, Nilsson SEG. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine: a study on patients with elevated intraocular pressure. Arch Ophthalmol 1993;111:662-5.
20. Neufeld AH, Bartels SP, Liu JH. Laboratory and clinical studies on the mechanism of action of timolol. Surv Ophthalmol 1983;28:Suppl:286-92.
21. Wax MB, Molinoff PB. Distribution and properties of beta-adrencrgic receptors in human iris-ciliary body. Invest Ophthalmol Vis Sci 1987;28: 420-30.
22. Dailey RA, Brubaker RF, Bourne WM. The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. Am J Ophthalmol 1982;93:232-7.
23. Musini A, Fabbri B, Bergamaschi M, Mandelli V, Shanks RG. Comparison of the effect of propranolol, lignocaine, and other drugs on normal and raised intraocular pressure in man. Am J Ophthalmol 1971;72:773-81.
24. McMahon CD, Shaffer RN, Hoskins HD Jr, Hetherington J Jr. Adverse effects experienced by patients taking timofol. Am J Ophthalmol 1979;88:736-8.
25. Van Buskirk EM. Adverse reactions from timolol administration. Oph-thalmology 1980;87:447-50.
26. Shore JH, Fraunfelder FT, Meyer SM. Psychiatric side effects from topical ocular timolol, a bera-adrenergic blocker. J Clin Psychopharmacol 1987;7:264-7.
27. Lynch MG, Whitson JT, Brown RH, Nguyen H, Drake MM. Topical beta-blocker therapy and central nervous system side effects: a preliminary study comparing betaxolol and timolol. Arch Ophthalmol 1988;106:908-11.
28. Orlando RG. Clinical depression associated with betaxolol. Am J Ophthalmol 1986;102:275.
29. Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, Kuritsky JN. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am J Ophthalmol 1986;102:606-11.
30. Jones FL Jr, Ekberg NL. Exacerbation of asthma by timolol. N Engl J Med 1979;301:270.
31. Avorn J, Glynn RJ, Gurwitz JH, et al. Adverse pulmonary effects of topical beta blockers used in the treatment of glaucoma. J Glaucoma 1993; 2:158-65.
32. Diggory P, Heyworth P, Chau G, McKenzie S, Sharma A, Luke I. Improved lung function tests on changing from topical timolol: non-selective beta-blockade impairs lung function tests in elderly patients. Eye 1993;7: 661-3.
33. Leier CV, Baker ND, Weber PA. Cardiovascular effects of ophthalmic timolol. Ann Intern Med 1986;104:197-9.
34. Pringle SD, MacEwen CJ. Severe bradycardia due to interaction of timolol eye drops and verapamil. BMJ 1987;294:155-6.
35. Dinai Y, Shark M, Naveh NN, Halkin H. Bradycardia induced by interaction between quinidine and ophthalmic timolol. Ann Intern Med 1985;103:890-1.
36. Atkins JM, Pugh BR Jr, Timewell RM. Cardiovascular effects of topical beta-blockers during exercise. Am J Ophthalmol 1985;99:173-5.
37. Doyle WJ, Weber PA, Meeks RH. Effect of topical timolol maleate on exercise performance. Arch Ophthalmol 1984;102:1517-8.
38. Fraunfelder FT. National Registry of possible drug-induced ocular side effects. Ophthalmology 1980;87:87-90.
39. Shaivitz SA. Timolol and myasthenia gravis. JAMA 1979;242:1611-2.
40. Velde TM, Kaiser FE. Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient. Arch Intern Med 1983;143:1627.
41. Coleman AL, Diehl DL, Jampel HD, Bachorik PS, Quigley HA. Topical timolol decreases plasma high-density lipoprotein cholesterol level. Arch Ophthalmol 1990;108:1260-3.
42. Zimmerman TJ, Baumann JD, Hetherington J Jr. Side effects of timolol. Surv Ophthalmol 1983;28:Suppl:243-51.
43. Schoene RB, Martin TR, Charan NB, French CL. Timolol-induced bronchospasm in asthmatic bronchitis. JAMA 1981;245:1460-1.
44. Edeki TI, He H, Wood AJJ. Pharmacogenetic explanation for excessive beta-blockade following timoiol eye drops: potential for oral-ophthalmic drug interaction. JAMA 1995;274:1611-3.
45. Freedman SF, Freedman NJ, Shields MB, et al. Effects of ocular carteolol and timoiol on plasma high-density lipoprotein cholesterol level. Am J Ophthalmol 1993;116:600-11.
46. West J, Longstaff S. Topical timoiol and serum lipoproteins. Br J Ophthalmol 1990;74:663-4.
47. Van Buskirk EM, Weinreb RN, Berry DP, Lustgarten JS, Podos SM, Drake MM. Betaxolol in patients with glaucoma and asthma. Am J Ophthalmol 1986;101:531-4.
48. Schoene RB, Abuan T, Ward RL, Beasley CH. Effects of topical betaxolol, timoiol, and placebo on pulmonary function in asthmatic bronchitis. Am J Ophthalmol 1984;97:86-92.
49. Harris LS, Greenstein SH, Bloom AF. Respiratory difficulties with betaxolol. Am J Ophthalmol 1986;102:274-5.
50. Nelson WL, Kuritsky JN. Early postmarkcting surveillance of betaxolol hydrochloride, September 1985-September 1986. Am J Ophthalmol 1987;103:592.
51. Vogel R, Tipping R, Kulaga SF, Clineschmidt CM, Timoiol-Betaxolol Study Group. Changing therapy from timoiol to betaxolol: effect on intraocular pressure in selected patients with glaucoma. Arch Ophthalmol 1989; 107:1303-7.
52. Bito LZ. Prostaglandins: old concepts and new perspectives. Arch Ophthalmol 1987;105:1036-9.
53. Waitzman MB, King CD. Prostaglandin influences on intraocular pressure and pupil size. Am J Physiol 1967;212:329-34.
54. Eakins KE. Increased intraocular pressure produced by prostaglandins E1 and E2 in the cat eye. Exp Eye Res 1970;10:87-92.
55. Alm A, Stjernschantz J, Scandavanian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timoiol. Ophthalmology 1995;102:1743-52.
56. Lutjen-Drecoll E, Tamm E. Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alpha. Exp Eye Res 1988;47:761-9.
57. Watson P, Stjernschantz J, Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timoiol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996;103:126-37.
58. Camras CB, United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. Ophthalmology 1996;103:138-47
59. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997;124:544-7.
60. Becker B, Morton WR. Topical epincphrine in glaucoma suspects. Am J Ophthalmol 1966;62:272-7.
61. Kerr CR, Hass I, Drance SM, Walters MB, Schulzcr M. Cardiovascular effects of epinephrine and dipivalyl epinephrine applied topically to the eye in patients with glaucoma. Br J Ophrhalmol 1982;66:109-14.
62. Lansche RK. Systemic reactions to topical epinephrine and phenylephrine. Am J Ophthalmol 1966;62:95-8.
63. Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996;41: Suppl 1:S27-S37.
64. Abrams DA, Robin AL, Pollack IP, deFaller JM, DeSantis L. The safety and efficacy of topical 1% ALO 2145 (p-aminoclondine hydrochloride) in normal volunteers. Arch Ophthalmol 1987;105:1205-7.
65. Nordlund JR, Pasquale LR, Robin AL, et al. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine. Arch Ophthalmol 1995;113:77-83.
66. Sears ML. The mechanism of action of adrenergic drugs in glaucoma. Invest Ophthalmol 1966;5:115-9.
67. Sears ML, Neufeld AH. Adrenergic modulation of the outflow of aqueous humor. Invest Ophthalmol 1975;14:83-6.
68. Tripathi BJ, Tripathi RC. Effect of epinephrine in vitro on the morphology, phagocytosis, and mitotic activity of human trabecular endothelium. Exp Eye Res 1984;39:731-44.
69. Kaback MB, Podos SM, Harbin TS Jr, Mandell A, Becker B. The effects of dipivalyl epinephrine on the eye. Am J Ophthalmol 1976;81:768-72.
70. Mandell AI, Stentz F, Kitabchi AE. Dipivalyl epinephrine: a new prodrug in the treatment of glaucoma. Ophthalmology 1978;85:268-75.
71. Theodore J, Leibowitz HM. External ocular toxicity of dipivalyi epinephrine. Am J Ophthalmol 1979;88:1013-6.
72. Harrison R, Kaufmann CS. Clonidine: effects of a topically administered solution on intraocular pressure and blood pressure in open-angle glaucoma. Arch Ophthalmol 1977;95:1368-73.
73. Macri FJ, Cevario SJ. Clonidine. Arch Ophthalmol 1978;96:2111-3.
74. Robin AL, Pollack IP, House B, Enger C. Effects of ALO 2145 on intraocular pressure following argon laser trabeculoplasty. Arch Ophthalmol 1987;105:646-50.
75. Robin AL, Pollack IP, deFaller JM. Effects of topical ALO 2145 (p-aminoclonidine hydrochloride) on the acute intraocular pressure rise after argon laser iridotomy. Arch Ophthalmol 1987;105:1208-11.
76. Coleman AL, Robin AL, Pollack IP, Rudikoff MT, Enger C, Mayer PR. Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine. Arch Ophthalmol 1990;108:1264-7.
77. Jampel HD, Robin AL, Quigley HA, Pollack IP. Apraclonidine: a one-week dose-response study. Arch Ophthalmol 1988;106:1069-73.
78. Butler P, Mannschreck M, Lin S, Hwang I, Alvarado J. Clinical experience with the long-term use of 1% apraclonidine: incidence of allergic reactions. Arch Ophthalmol 1995;113:293-6.
79. Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol 1996;41:Suppl I:S9-S18.
80. Friedenwald JS. Current studies on acetaxoleamide (Diamox) and aqueous humor flow. Am J Ophthalmol 1955;40:139-47.
81. Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects. Arch Ophthalmol 1977;95:1378-82.
82. Wallace TR, Fraunfelder FT, Petursson GJ, Epstein DL. Decreased libido - a side effect of carbonic anhydrase inhibitor. Ann Ophthalmol 1979;11: 1563-6.
83. Epstein RJ, Alien RC, Lunde MW. Organic impotence associated with carbonic anhydrase inhibitor therapy for glaucoma. Ann Ophthalmol 1987; 19:48-50.
84. Heller I, Halevy J, Cohen S, Theodor E. Significant metabolic acidosis induced by acetazolamide: not a rare complication. Arch Intern Med 1985; 145:1815-7.
85. Kass MA, Kolker AE, Gordon M, et al. Acetazolamide and urolithiasis. Ophthalmology 1981;88:261-5.
86. Howlett SA. Renal failure associated with acetazolamide therapy for glaucoma. South Med J 1975;68:504-6.
87. Higenbottam T, Ogg CS, Saxton HM. Acute renal failure from the use of acetazolamide (Diamox). Postgrad Med J 1978;54:127-8.
88. Fraunfelder FT, Meyer SM, Bagby GC Jr, Dreis MW. Hematologie reactions to carbonic anhydrase inhibitors. Am J Ophthalmol 1985;100:79-81.
89. Werblin TP, Pollack IP, Liss RA. Blood dyscrasias in patients using methazolamide (Neptazane) for glaucoma. Ophthalmology 1980;87:350-4.
90. Weiss IS. Hirsutism after chronic administration of acetazolamide. Am J Ophthalmol 1974;78:327-8.
91. Shirato S, Kagaya F, Suzuki Y, Joukou S. Stevens-Johnson syndrome induced by methazolamide treatment. Arch Ophthalmol 1997;115:550-3.
92. Becker B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, Diamox: a preliminary report. Am J Ophthalmol 1954;37: 13-5.
93. Wisch N, Fischbein FI, Siegel R, Glass JL, Leopold I. Aplastic anemia resulting from the use of carbonic anhydrase inhibitors. Am J Ophthalmol 1973;75:130-2.
94. Lippa EA, Schuman JS, Higginbotham EJ, et al. MK-507 versus sezolamide: comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology 1991;98:308-12.
95. Gunning FP, Greve EL, Bron AM, et al. Two topical carbonic anhydrase inhibitors sezolamide and dorzolamide in Gelrite vehicle: a multiple-dose efficacy study. Graetes Arch Clin Exp Ophthalmol 1993;231:384-8.
96. Laibovitz R, Strahlman ER, Barber BL, Strohmaier KM. Comparison of quality of life and patient preference of dorzolamide and pilocarpine as adjunctive therapy to timolol treatment of glaucoma. J Glaucoma 1995;4: 306-13.
97. Kronfeld PC. Eserine and pilocarpine: our 100-year-old allies. Surv Ophthalmol 1970;14:479-85.
98. Kaufman PL, Barany EH. Loss of acute pilocarpine effect on outflow facility following surgical disinsertion and retrodisplacement of the ciliary muscle from the scleral spur in the cynomolgus monkey. Invest Ophthalmol 1976;15:793-807.
99. Greco JJ, Kelman CD. Systemic pilocarpine toxicity in the treatment of angle closure glaucoma. Ann Ophthalmol 1973;5:57-9.
100. Reyes PF, Dwyer BA, Schwartzman RJ, Sacchetti T. Mental status changes induced by eye drops in dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 1987;50:113-5.
101. Hiscox PEA, McCulloch C. The effect of echothiophate iodide on systemic cholinesterasc. Can J Ophthalmol 1966;1:274-82.
102. Curti PC, Renovanz H-D. Die Wirkung akzidenteller Uberdosierung von Pilocarpin auf den pulmonalen Surfaktant an der Maus. Klin Monatsbl Augenheilkd 1981;179-113-5.
103. Ellis PP, Littlejohn K. Effects of topical anticholinesterases on procaine hydrolysis. Am J Ophthalmol 1974;77:71-5.
104. Harris LS, Galin MA. Dose response analysis of pilocarpine-induced ocular hypotension. Arch Ophthalmol 1970;84:605-8.
105. Reichert RW, Shields MB. Intraocular pressure response to the replacement of pilocarpine or carbachol with echothiophate. Graefes Arch Clin Exp Ophthalmol 1991;229:252-3.
106. De Roetth A Jr. Lens opacities in glaucoma patients on phospholine iodide therapy. Am J Ophthalmol 1966;62:619-28.
107. Goldberg I, Ashburn FS Jr, Kass MA, Becker B. Efficacy and patient acceptance of pilocarpine gel. Am J Ophthalmol 1979;88:843-6.
108. Armaly MF, Rao KR. The effect of pilocarpine Ocusert with different release rates on ocular pressure. Invest Ophthalmol 1973;12:491-6.
109. Hepler RS, Frank IR. Marihuana smoking and intraocular pressure. JAMA 1971;217:1392.
110. Merritt JC, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology 1980;87:222-8.
111. Merritt JC, McKinnon S, Armstrong JR, Hatem G, Reid LA. Oral delta9-tetrahydrocannabinol in heterogeneous glaucomas. Ann Ophthalmol 1980;12:947-50.
112. Purnell WD, Gregg JM. Delta(9)-tetrahydrocannabinol, euphoria and intraocular pressure in man. Ann Ophthalmol 1975;7:921-3.
113. Merritt JC, Olsen JL, Armstrong JR, McKinnon SM. Topical delta 9-tetrahydrocannabinol in hypertensive glaucomas. J Pharm Pharmacol 1981;33:40-1.
114. Green K, Roth M. Ocular effects of topical administration of delta 9-tetrahydrocannabinol in man. Arch Ophthalmol 1982;100:265-7.
115. Jay WM, Green K. Multiple-drop study of topically applied 1% delta 9-terrahydrocannabinol in human eyes. Arch Ophthalmol 1983;101:591-3.
116. Gaasterland DE. Efficacy in glaucoma treatment - the potential of marijuana. Ann Ophthalmol 1980;12:448-50.
117. Kaiser HJ, Flammer J, Messmer C, Stümpfig D, Hendrickson P. Thirty-month visual field follow-up of glaucoma patients treated with beta-blockers. J Glaucoma 1992;1:153-5.
118. Stone EM, Fingert JH, Alward WLM, et al. Identification of a gene that causes primary open angle glaucoma. Science 1997;275:668-70.